



GANT 61

Catalog No: tcsc1528

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Specifications
CAS No: 500579-04-4
Formula: C ₂₇ H ₃₅ N ₅
Pathway: Autophagy;Stem Cell/Wnt
Farget: Autophagy;Gli
Purity / Grade: >98%
Solubility: DMSO: 17.6 mg/mL (40.97 mM; Need ultrasonic and warming)
Alternative Names: NSC 136476
Observed Molecular Weight: 129.6

Product Description





GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.

IC50 & Target: Gli1/2^[1]

In Vitro: GANT61 (20 μM) induces greater cell death than targeting Smo (cyclopamine). GANT61 (0, 5, 10, 20 μM) inhibits clonogenic survival of human colon carcinoma cell lines. GANT61 (20 μM, 0-72 hr) down-regulates Gli1 and Gli2 expression in HT29 cells. GANT61 (0, 10 μM or 20 μM) differentially regulates genes involved in the balance between cell death and cell survival^[1]. GANT-61 inhibits cell viability and induces apoptosis in pancreatic CSCs. GANT-61 inhibits expression of downstream targets of Shh pathway, decreases Gli-DNA interaction, Gli transcriptional activity and Gli nuclear translocation in pancreatic CSCs. GANT-61 differentially regulates genes involved in cell survival, cell death and pluripotency. GANT-61 inhibits motility, invasion and migration of CSCs^[2]. GANT61 sensitivity positively correlates to GLI1 and negatively to MYCN expression in the neuroblastoma cell lines tested. GANT61 downregulates GLI1, c-MYC, MYCN and Cyclin D1 expression and induces apoptosis of neuroblastoma cells^[3].

In Vivo: GANT-61 (40 mg/kg, i.p., three days per week) inhibits CSC tumor growth in NOD/SCID IL2Rγ null mice^[2]. GANT61 (50 mg/kg, p.o.) enhances the effects of chemotherapeutic drugs used in the treatment of neuroblastoma in an additive or synergistic manner and reduces the growth of established neuroblastoma xenografts in nude mice^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!